Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin's lymphoma. Although many investigations have been performed on the prognostic factors of DLBCL, no reports have focused on localized nodal DLBCL. We examined the prognostic significance of 39 Japanese patients with localized nodal DLBCL with special reference to the germinal center B-cell-like (GCB) versus non-germinal center B-cell-like (NGCB) types. The median age was 65 years with 23 males and 16 females. Using Hans algorithm of immunohistochemistry, 18 patients (46%) exhibited GCB type and 21 (54%) exhibited NGCB type. Twenty-nine patients (74%) presented with disease in the neck (neck group) and 10 (26%) had disease in non-neck regions (non-neck group). Comparing Hans, Choi, and Muris algorithms, patients with GCB type showed statistically significant progression-free survival (PFS) only with Hans algorithm (P = 0.022, P = 0.100, and P = 0.130, respectively). Patient survival analyses revealed that GCB-type patients by Hans algorithm had a better PFS (P = 0.012), and neck-group patients had better PFS and overall survival (OS) (P = 0.018 and P = 0.012, respectively). Univariate analysis revealed that only neck vs. non-neck exhibited a significant difference in terms of OS (P = 0.026). Multivariate analysis revealed that GCB type by Hans algorithm and neck vs. non-neck were significantly different in terms of PFS (P = 0.025 and P = 0.033, respectively). Therefore, the subclassifications of GCB type vs. NGCB type and neck vs. non-neck are important predictive prognostic factors in localized nodal DLBCL. 〔J Clin Exp Hematopathol 52(2) : 91-99, 2012〕 
INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin's lymphoma (NHL). 1, 2 Approximately 60% of all DLBCL cases primarily occur in the lymph node. 3, 4 Previous studies have shown that patients with nodal DLBCL exhibited increased frequency of bulky growth, increased bone marrow metastasis, and high serum LDH titers compared with those with extranodal DLBCL. 4 Molecular studies, including those on Bcl-2, Bcl-6, and MYC, have also indicated significant phenotypic differences between nodal and extranodal DLBCL. [5] [6] [7] [8] Studies have generally focused on both nodal and extranodal DLBCL ; however, there are no detailed studies characterizing nodal DLBCL, particularly localized I and II nodal DLBCL stages. DLBCL generally exhibits strong heterogeneity in morphology, immunophenotyping, genetics, and other clinical features. The International Prognostic Index (IPI) is one of the most important clinical indicators of prognosis in NHL cases.
Recent analysis of the cDNA expression profile characterized two separate DLBCL types, germinal center B-cell-like (GCB) and activated B-cell-like (ABC). GCB type has significantly higher survival rate than ABC type. 10 Although several algorithms have divided DLBCLs into GCB, ABC, or non-germinal B-cell-like (NGCB) type using an immunohistochemical panel, [11] [12] [13] [14] [15] no study has investigated localized nodal DLBCL. Therefore, in this study, we clinicopathologically examined 39 Japanese patients with localized nodal DLBCL.
MATERIALS AND METHODS

Patients and materials
Thirty-nine Japanese patients with stage I and II nodal DLBCL were selected on the basis of the availability of clinical information and histological material. These were consecutive cases retrieved from the records of Chugoku Central Hospital and Toyama Prefectural Hospital, Japan, from 1997 to 2008. The histopathology of each DLBCL was reviewed by 3 pathologists (YS, TT, and TY). For accurate staging, the extent of the disease was determined by a standardized range of examinations, including neck, thoracic, abdominal, and pelvic computed tomography scans and/or positron emission tomography, as well as bone marrow biopsies. The study was conducted in accordance with the provisions of the Declaration of Helsinki and was approved by the ethics committee of Chugoku Central Hospital.
Antibodies
The primary antibodies used were as follows : Bcl-2 (3.1, 1:400 ; Novocastra, Newcastle upon Tyne, UK), CD3 (LN10, 1:800 ; Novocastra), CD5 (4C7, 1:400 ; Novocastra), CD10 (56C6, 1:100 ; Novocastra), CD20 (L26, 1:200 ; Novocastra), MUM1 (MUM1p, 1:200 ; Dako, Glostrup, Denmark), Bcl-6 (polyclonal, 1:300 ; Dako), p53 (Pab1801, 1:2,000 ; Santa Cruz Biotechnology, Delaware Avenue, CA, USA), GCET1 (RAM341, 1:100 Abcam, Cambridge, UK), FOXP1 (JC12, 1:500 LifeSpan Biosciences, Seattle, WA, USA), and Ki-67 (MIB-1, 1:1,500 ; Novocastra).
Histological examination, immunohistochemistry, and in situ hybridization (ISH)
Surgically resected or biopsied specimens were fixed in 10% formaldehyde and routinely embedded in paraffin. Three-micrometer-thick serial sections were stained with hematoxylin-eosin. Immunohistochemistry was performed on paraffin sections using the Bond automated immunohistochemistry system (Leica Biosystems, Melbourne, Australia). For each section, 10 high-power fields were recorded, quantitated, and averaged for the estimated percentage of positively immunostained cells. DLBCL of at least 30% tumor cells was the cut-off for tumor positivity, except where noted in the Choi algorithm. Ki-67 immunoreactivity was quantified by determining the number of positive cells among the tumor cells. 16 ISH with Epstein-Barr virus-encoded small RNA (EBER) oligonucleotides was performed to test for the presence of EBER in formalin-fixed paraffin-embedded sections using the Bond automated immunohistochemistry system.
Statistical analysis
Differences in characteristics between the two groups were examined by the Chi-square test, Fisher's exact test, Student's t-test, and the Mann-Whitney U test as appropriate. Patient survival data were analyzed by the Kaplan-Meier method. Differences in survival rates were tested by the logrank test. 17 Progression-free survival (PFS) rates were measured from the time of initial diagnosis to that of disease relapse. Overall survival (OS) rates were measured from the time of initial diagnosis to that of death or last follow-up. Univariate and multivariate analyses were performed with Cox proportional hazards regression models. 18 Results are expressed as hazard ratio and 95% confidence interval. All data were analyzed using STATA software (version 10.0, Stata Corp., Texas, USA).
RESULTS
Characterization of patients with localized stage I and II nodal DLBCL
The clinical findings are summarized in Table 1 . The median age of the 39 patients (23 men and 16 women) with localized nodal DLBCL was 65 years (range 33-79 years). Twenty-nine patients (74%) presented with disease in the neck, four (10%) in the inguinal area, four (10%) in the axilla, one (3%) in the hilar, and one (3%) in the abdomen. Thirtythree patients (85%) were at low risk, five (12%) were at lowintermediate risk, and one (2%) was at high-intermediate risk according to IPI. 9 Seven patients (18%) exhibited elevated serum lactate dehydrogenase (LDH) titer levels, while 32 (82%) exhibited normal serum LDH titer levels. According to the Ann Arbor classification, 19 patients (49%) were at clinical stage I and 20 (51%) were at clinical stage II. Histopathologically, all 39 cases were classified as DLBCL. No patient had a history of prior therapy. They were initially and primarily treated with standard anthracycline combination chemotherapy with a predominant cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) regimen. Sixteen patients (41%) who received their first round of chemotherapy after September 2003 were treated with CHOP and rituximab.
Immunohistochemical and ISH analyses of localized nodal DLBCL
Immunohistological positivity of tumor cells in > 30% of localized nodal DLBCL was observed for several antigens : CD5 in two cases (5%), CD10 in 16 cases (41%), CD20 in 39 cases (100%), Bcl-6 in 31 cases (79%), Bcl-2 in 25 cases (64%), p53 in 19 cases (49%), and MUM1 in 28 cases (72%). Immunohistological positivity of tumor cells in > 80% of localized nodal DLBCL was also observed for several antigens : including MUM1 in eight cases (21%), GCET1 in 17 cases (44%), FOXP1 in 32 cases (83%), and Ki-67 in 10 cases (26%) ( Table 2) .
Using Hans algorithm, 11 18 cases (46%) were categorized as GCB type and 21 (54%) were categorized as NGCB type (Fig. 1) . Using Choi algorithm, 12 21 cases (54%) were categorized as GCB type and 18 (46%) were categorized as ABC type. Using Muris algorithm, 13 25 cases (64%) were categorized as Group 1 (GCB) and 14 (36%) as Group 2 (ABC). No cases were positive for EBER by ISH. 
Survival analysis of patients with localized stage I and II nodal DLBCL
The duration of the follow-up study ranged from 4 to 146 months (mean 56 months). Twenty-one patients were initially treated with chemotherapy plus irradiation, 17 with chemotherapy alone, and one with irradiation alone. All 39 patients had complete remission, but 16 patients relapsed thereafter (Table 1) . Of the relapsed patients, 13 exhibited relapse at different primary nodes and/or organs (relapsed lesion of four patients also involved the primary site). The remaining three patients exhibited relapse at the primary site (Table 3) .
Seven of the patients who exhibited relapse at the primary site underwent chemotherapy and/or radiation treatment.
Three of 11 (27%) patients treated with chemotherapy plus irradiation exhibited relapse at the primary site, while four of five (80%) patients treated with only chemotherapy exhibited relapse.
According to the Kaplan-Meier method, the 5-year PFS rate was 56% and the 5-year OS rate was 71%. When the cases were categorized into GCB and NGCB types based on Hans algorithm, patients with GCB type had a better PFS rate than those with NGCB type (P = 0.012) (Fig. 2) . When the cases were divided into neck and non-neck groups for the primary site, patients in the neck group had better 5-year PFS and OS rates than those in the non-neck group (P = 0.018 and P = 0.012, respectively) (Fig. 3a, 3b) .
As shown in Tables 4 and 5 , univariate Cox proportional hazards regression analysis revealed that GCB type, GCB or NGCB type by Hans algorithm, and the primary node site (neck versus non-neck) exhibited significant differences in terms of 5-year PFS rate (P = 0.022 and P = 0.027, respectively). Using Choi and Muris algorithms, GCB type showed no significant difference in terms of PFS rate (P = 0.100 and P = 0.130, respectively). Only the primary node site (neck versus non-neck) showed significantly different 5-year OS rates (P = 0.026). Multivariate Cox proportional hazards regression analysis revealed that both GCB type and the primary node sites (neck versus non-neck) exhibited significant differences in terms of PFS rates (P = 0.025 and P = 0.033, respectively) ( Table 6 ). 
DISCUSSION
Previous reports have indicated that not only IPI but also other serum markers, such as LDH, soluble interleukin-2 receptor, and albumin, have important roles. [19] [20] [21] In particular, a high LDH titer is detected in nodal lymphomas at a greater frequency than in extranodal lymphomas. 4 In the present study, LDH titer levels were within the normal range in 82% of the patients.
Many recent reports have mentioned that CHOP chemotherapy with rituximab had better outcomes than CHOP alone. [22] [23] [24] However, in the present study, we observed that patients treated with CHOP and rituximab were not significantly different from those given CHOP alone, demonstrating that rituximab did not improve prognosis. This finding suggests that the usefulness of rituximab should be reconsidered for localized nodal cases.
We also observed that, following chemotherapy, relapse in 13 of 16 patients occurred at sites other than the primary site. This result was similar to the results of previously published studies 25, 26 and strongly indicates the importance of performing systemic medical examinations on patients after therapy, even during the early stages of nodal DLBCL.
It is well known that irradiation therapy reveals the effective local control of DLBCL. 27 In the present study, relapse at the primary site was more often seen in patients treated with chemotherapy alone than in those treated with chemotherapy plus irradiation.
Many investigators have also reported the use of various algorithms concerning GCB phenotypes. Meyer et al. stressed that the algorithms of Hans and Choi are useful in determining the cell origin and can separate patients into prognostic groups. In the present study, we compared the algorithms of Hans, Choi, and Muris. Hans algorithm utilizes In the present study, univariate analysis showed that the primary site of lymph nodes retained its prognostic value for both 5-year PFS and OS rates. Multivariate analysis also showed that the primary site of the lymph nodes can act as an independent prognostic indicator in the 5-year PFS rate. To the best of our knowledge, this is a novel finding on localized nodal DLBCL and was an unexpected discovery. There was no apparent difference between the neck and non-neck groups with regard to IPI, clinical stage, tumor size, proportion of patients treated with rituximab, or age. Because patients not treated with rituximab were included in the present study, further research should be conducted on a larger number of rituximab-treated patients in order to draw a clear conclusion.
We obtained clinical data of localized DLBCL from patients who underwent uniform treatment strategies at two separate institutes. It is well known that the prognosis of extranodal DLBCL is dependent on the primary site. 4 Similarly, in the nodal DLBCLs, the primary site may also be one of the more important prognostic factors. Therefore, we believe that classification of localized nodal DLBCL into the neck vs. non-neck subgroups is useful for predicting prognosis.
We also analyzed CD5 and EBER expression and detected two CD5-positive cases (5%), but EBER was not detected. CD5-and EBER-positive DLBCLs may be poor prognostic markers ; 28, 29 univariate analysis exhibited no significant difference in PFS and OS survival rates.
In conclusion, the subclassification of GCB type versus NGCB type and the primary node site is important in the prediction of prognosis in patients with localized nodal DLBCL.
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